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Abstract
Background: Two year cancer bioassays conducted by the National Toxicology Program have shown chronic
exposure to dioxin-like compounds (DLCs) to lead to the development of both neoplastic and non-neoplastic
lesions in the hepatic tissue of female Sprague Dawley rats. Most, if not all, of the hepatotoxic effects induced by
DLC’s are believed to involve the binding and activation of the transcription factor, the aryl hydrocarbon receptor
(AhR). Toxicogenomics was implemented to identify genomic responses that may be contributing to the
development of hepatotoxicity in rats.
Results: Through comparative analysis of time-course microarray data, unique hepatic gene expression signatures were
identified for the DLCs, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/day) and 3,3’,4,4’,5-pentachlorobiphenyl
(PCB126) (1000 ng/kg/day) and the non-DLC 2,2’,4,4’,5,5’,-hexachlorobiphenyl (PCB153) (1000 μg/kg/day). A common
time independent signature of 41 AhR genomic biomarkers was identified which exhibited at least a 2-fold change in
expression following subchronic (13-wk) and chronic (52-wk) p.o. exposure to TCDD and PCB126, but not the non DLC,
PCB153. Real time qPCR analysis validated that 30 of these genes also exhibited at least a 2-fold change in hepatic
expression at 24 hr following a single exposure to TCDD (5 μg/kg, po). Phenotypic anchoring was conducted which
identified forty-six genes that were differently expressed both following chronic p.o. exposure to DLCs and in previously
reported studies of cholangiocarcinoma or hepatocellular adenoma.
Conclusions: Together these analyses provide a comprehensive description of the genomic responses which occur
in rat hepatic tissue with exposure to AhR ligands and will help to isolate those genomic responses which are
contributing to the hepatotoxicity observed with exposure to DLCs. In addition, the time independent gene
expression signature of the AhR ligands may assist in identifying other agents with the potential to elicit dioxin-like
hepatotoxic responses.
Background
Dioxin-like compounds (DLCs) such as polychlorinated
biphenyls (PCBs) and polychlorinated dibenzo-p-dioxins
(PCDDs) are prevalent contaminants which pose a risk to
both public health and the environment. Exposure to
PCBs and PCDDs has been associated with numerous
adverse biological effects including reproductive toxicity,
dermatotoxicity, immunotoxicity, developmental toxicity,
neurotoxicity, carcinogenesis and hepatotoxicity [1-5].
The carcinogenic and hepatotoxic effects of DLCs have
been shown to be gender dependent, with female
rats being more susceptible than male rats [6]. The
DLCs, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and
3,3’,4,4’,5-pentachlorobiphenyl (PCB126); and the non-
DLC 2,2’,4,4’,5,5’,-hexachlorobiphenyl (PCB153) were
investigated by the National Toxicology Program in a
two-year cancer bioassay evaluating their hepatotoxic
and carcinogenic properties in female Sprague-Dawley
(SD) rats [4,5,7,8]. Following 104 weeks of chronic p.o.
exposure to TCDD (100 ng/kg/day) or PCB126 (1000 ng/
kg/day), a significant and similar increase in the inci-
dence and range of non-neoplastic and neoplastic lesions
were observed in the livers of female rats (Table 1) [4,5].
The non-neoplastic lesions included, but were not
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duct hyperplasia, oval cell hyperplasia, fatty diffuse
change, necrosis, inflammation and cholangiofibrosis.
The neoplastic lesions included hepatocellular adenoma
and cholangiocarcinoma. A significant increase in the
incidence of 6 of these non-neoplastic lesions and no
neoplastic lesions were also observed following 52 weeks
of exposure to TCDD or PCB126, while only hepatocyte
hypertrophy was observed following 13 weeks of expo-
sure (Table 1). Thus, the range of hepatotoxic responses
to these DLCs is directly dependent on the duration of
exposure. In comparison, chronic exposure (104 weeks) to
the non-DLC PCB153 (1000 μg/kg/day) only caused a sig-
nificant increase in the incidence of two non-neoplastic
lesions (hepatocyte hypertrophy and diffuse fatty
change) and did not lead to the formation of neoplasia
(Table 1) [8].
Most, if not all, of the hepatotoxic effects induced by
DLCs are believed to involve the binding and activation
of the aryl hydrocarbon receptor (AhR). Ligand activa-
tion of the AhR induces changes in gene expression and
function which are believed to be the major contributing
factor to the development of hepatotoxicity, carcinogeni-
city and other toxic responses of DLCs. DLC-induced
AhR-independent genomic and cellular responses have
also been reported [9,10], however, these responses
likely do not play a major role in the development of
hepatotoxicity induced by DLCs. The importance of the
AhR in DLC-induced toxicity has been determined in
acute studies conducted with female AhR knockout
mice. Toxic effects that were observed in wild type mice
but were absent in AhR knockout mice, included wast-
ing syndrome, thymic atrophy, lipid accumulation in
hepatocytes (diffuse fatty change) and liver hypertrophy
[11,12]. Acute TCDD toxicity is also gender, species and
strain specific. Following acute exposure to TCDD,
female Sprague Dawley rats exhibit a greater down-regu-
lation in gene expression compared to male rats [13].
Sprague Dawley rats and C57BL/6 mice exhibit different
hepatic gene expression profiles following acute TCDD
exposure with rat-specific gene responses being asso-
ciated with lipid metabolism and cell growth while
mouse-specific responses are involved in immune func-
tion and lipid uptake/metabolism [14]. Long-Evans rats
and Han/Wistar rats exhibit a 1000-fold difference in
sensitivity to acute TCDD lethality [15] which is attribu-
t e dt oap o i n tm u t a t i o ni nt h eA h Rp r o t e i no fH a n /
Wistar rats [16]. This suggests that the acute toxic
effects of TCDD are dependent on AhR functionality,
gender, species and strain, and suggest that the chronic
toxic effects of DLCs are also mediated through persis-
tent AhR activation.
Table 1 Neoplastic and non-neoplastic lesions observed in hepatic tissue of female Sprague-Dawley rats following 104
weeks of chronic p.o. exposure
100 ng/kg/day
TCDD
30 ng/kg/day
PCB126
300 ng/kg/day
PCB126
1000 ng/kg/day
PCB126
1000 μg/kg/day
PCB153
Number of Rats
Examined
53 55 53 53 53
Hepatocyte Hypertrophy 52**
a 23** 42**
a 49**
a 39**
a
Multinucleated
Hepatocytes
51**
b 2 19** 49**
b NA
Fatty Change, Diffuse 48**
b 7 30** 47**
b 21**
Bile Duct Hyperplasia 53**
b 7 14** 45**
b 10
Bile Duct Cyst 21** 6 3 12* NA
Oval Cell, Hyperplasia 53** 1 10** 40** NA
Necrosis 17** 2 11 17** NA
Pigmentation 53**
b 11** 48**
b 48**
b 5
Eosiniphilic Focus 44** 10 17 17 NA
Inflammation 49** 40 51** 51** NA
Nodular Hyperplasia 36** NA 3 39** 1
Portal Fibrosis 27** NA 2 10** NA
Cholangiofibrosis 31** 1 3 22** 1
Toxic Hepatopathy 53**
b 6* 39** 49**
b NA
Hepatocholangioma 17** NA NA 3 2
Hepatocellular Adenoma 13** 2 2 7* NA
Cholangiocarcinoma 25** NA 5* 22** NA
Shown are the number of animals in each treatment group which exhibit the indicated liver pathology following exposure to TCDD (100 ng/kg/day), PCB126 (30,
300 or 1000 ng/kg/day) or PCB153 (1000 μg/kg/day). Data acquired from the National Toxicology Program [4,5,8].
a Response also significantly increased (p ≤
0.01) following 13 and 52 weeks of exposure;
b Response also significantly increased (p ≤ 0.01) following 52 weeks of exposure; * Statistically significant when
compared to control with p-value ≤ 0.05; ** Statistically significant when compared to control with p-value ≤ 0.01; NA - not available.
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t i cg e n ee x p r e s s i o ni nr e s p o n s et oA h Rl i g a n d sa n d
non-ligands following acute and 13 weeks of exposure,
which were associated with liver hypertrophy in the
absence of other hepatotoxic effects [13,17]. Although
these studies have led to a better understanding of the
acute and subchronic genomic responses to DLCs, the
evaluation of hepatic gene expression following chronic
exposure to DLCs is needed to effectively identify geno-
mic factors that may be contributing to the hepatotoxic
effects of these toxins which are observed following 52
and 104 weeks of exposure (see Table 1). Building on
previous microarray experiments, comparative analysis
was conducted between microarray data from subchro-
nic (13 weeks) and chronic (52 weeks) time-points to
identify genomic biomarkers that are sustained through-
out chronic exposure. Genomic biomarkers that were
shared by TCDD and PCB126, but not PCB153, were
further analyzed for their acute responsiveness to ascer-
tain a subset of genes which may serve as time-indepen-
dent genomic biomarkers of exposure to AhR ligands in
the female SD rat model. Finally, to relate differential
hepatic gene expression to the liver pathology observed
with chronic exposure to DLCs, phenotypic anchoring
was conducted to associate differentially expressed genes
with hepatocellular adenoma and cholangiocarcinoma.
Together these analyses will provide a comprehensive
description of the genomic responses which occur in rat
h e p a t i ct i s s u ew i t hs u b c h r o n i ca n dc h r o n i ce x p o s u r et o
AhR ligands and will help to isolate those genomic
responses which are contributing to the hepatotoxicity
observed with chronic exposure to DLCs.
Methods
Animal Exposures and Procurement of Liver Tissue
Liver tissues were obtained from the National Toxicology
Program (NTP) 2-year cancer bioassay investigating the
relative carcinogenic potencies of the AhR ligands TCDD
and PCB126; and the non-ligand PCB153 [4,5,8]. Female
SD rats were exposed 5 days a wk via oral gavage to toxi-
cologically equivalent doses of TCDD (100 ng/kg/day)
(Toxic equivalence factor (TEF) = 1.0), PCB126 (30 ng,
300 ng or 1000 ng/kg/day) (TEF = 0.1), PCB153 (1000
μg/kg/day) (TEF = 0.0) or a vehicle control of corn oil:
acetone (99:1). Rats were exposed to these compounds
for 13 wks (subchronic exposure) or 52 wks (chronic
exposure). TEFs were determined using the 2005 TEF
recommendations provided by the World Health Organi-
zation [18]. Liver tissue was also harvested from female
SD rats at 24 hr following a single exposure to TCDD
(5 μg / k g ,p o ) .T h i se x p o s u r ew a sc o n d u c t e dt oi d e n t i f y
early responsive genes which were also shown to be dif-
ferentially expressed (up- or down-) following exposures
to DLCs. This acute dose of TCDD has been previously
shown to result in hepatic tissue concentrations of dioxin
similar to those observed with subchronic and chronic
exposure [13]. All procedures were carried out with the
approval of the University at Buffalo Institutional Animal
Care and Use Committee (PMY14098Y).
RNA Isolation and Hybridization
The storage and processing of liver samples was
described earlier by Vezina et al. 2004. Following sto-
rage at -80°C, liver tissues were disrupted by homogeni-
zation and total RNA was isolated with the Qiagen
RNeasy kit (Qiagen Inc., Valencia, CA). RNA integrity
was assessed using the Agilent Bioanalyzer 2100 (Agilent
Technologies, Palo Alto, CA). High quality RNA was
transformed into biotinylated cRNA by the Roswell Park
Cancer Institute Gene Expression Facility (Buffalo, NY)
and hybridized to RGU34A GeneChips (Affymetrix,
Santa Clara, CA) and scanned with the Affymetrix 428
scanner.
Gene Microarray Data Analysis
Probe-level data from cell intensity files were back-
ground subtracted and normalized by the gc-Robust
Multiarray Analysis (gcRMA) method using ArrayAssist®
(Stratagene, CA). Absolute fold changes and t-test statis-
tics (including Benjamini-Hochberg false discovery rate
(FDR) corrections) were calculated using ArrayAssist®.
Probe-sets were filtered to identify those genes which
exhibited a change in expression (up- or down-) of at
least 2-fold and a t-test p-value ≤ 0.05 between treated
(n = 3) and control (n = 3) groups. Comparative analysis
was conducted using Microsoft excel (Microsoft Cor-
poration, Redmond, WA) to further filter the data and
identify genes that exhibited statistically significant
change (≥ 2-fold) with two or more toxicants. Gene
annotation and gene symbols were obtained through the
Affymetrix NetAffx™ Analysis Center Software. Heat
maps were constructed using TIGR Microarray Experi-
ment Viewer 4.0 [19]. Student t-tests and ANOVA ana-
lysis with the post-hoc Tukey test were conducted
between treatment groups using Minitab™ (Minitab Inc.,
State College, PA). A complete summary of gene micro-
a r r a yd a t ai sa v a i l a b l et h r o u g ht h eG e n eE x p r e s s i o n
Omnibus at the National Center for Biotechnology
Information at http://www.ncbi.nlm.nih.gov/geo/ as
accession numbers GSE5789 (13 week microarray data)
and GSE22263 (52 week microarray data).
Quantitative Real-time PCR analysis
Quantitative real-time polymerase chain reaction (qPCR)
validated the hepatic expression of AhR genomic bio-
markers in livers from rats at 24 hr following exposure
to TCDD (5 μg/kg, po). Primers were selected from
Entrez Gene rat gene reference sequences using Primer3
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described previously [17] and primer sequences are
listed in additional file 1. Real-time qPCR was con-
ducted on hepatic cDNA using the IQ SYBR green
supermix kit (Bio-Rad Laboratories, Hercules, CA) as
described previously in Ovando et al. (2006). Statistical
comparisons of control vs. treated groups was per-
formed with a 2-sample t-test using Minitab 15 statisti-
cal software (Minitab Inc., State College, PA)
Identification of Dioxin Response Elements (DREs)
Gene regulatory regions spanning 5000 bp above and
1000 bp below the transcriptional start site of target
genes were obtained from the University of California,
Santa Cruz, Genome Browser using Entrez Gene Gen-
eID numbers. All obtained sequences were analyzed for
core DRE sequences (5’-GCGTG-3’) using MatInspector
(Genomatix Software GmbH, Munchen, Germany).
Putative DREs were those with a core similarity of 1.0
and matrix similarity equal to or greater than the opti-
mized matrix threshold [21].
Phenotypic Anchoring of Gene Expression Data
Changes in gene expression associated with TCDD,
PCB126 and PCB153 exposure were compared with
changes in gene expression associated with rat hepatocel-
lular adenoma (HCA) [22], human HCA [23]and human
intrahepatic cholangiocarcinoma (ICC) [24,25]. Eighty-
one percent of the human HCA tumors were from males
[23] while 52% [24] and 41% [25] of the human ICC
tumors were from males. Our approach was limited in
that the HCA and ICC expression data was not reported
on a gender specific basis thus preventing us from identi-
fying shared gene responses based on gender. Ortholog
identification and gene annotation of gene array data
obtained from published studies was accomplished using
ArrayTrack (Food and Drug Administration, NTCR)
and/or NetAffix™ (Affymetrix Inc.) [26].
Results
Dose-response Analysis of Hepatic Gene Expression
following Chronic Exposure to 30 ng, 300 ng and
1000 ng/kg/day PCB126
Increases in the incidence of non-neoplastic and neo-
plastic hepatic lesions were observed with increasing
dose and duration of exposure to PCB126 (Table 1) [5].
To evaluate the effect of increasing dose of PCB126 on
hepatic gene expression, microarray analysis was con-
ducted on hepatic tissue of female SD rats following 52
weeks of chronic exposure to 30 ng, 300 ng and 1000
ng/kg/day PCB126. Gene array analysis showed a posi-
tive trend between PCB126 dose and the number of
genes differentially expressed (Table 2). In addition, the
magnitude of differential expression of several genes
also increased with increasing dose of PCB126 (addi-
tional files 2, 3 and 4). Sixteen genes were identified
which exhibited altered expression at all three doses
(Table 3). Four of the sixteen genes were classic AhR
responsive genes and exhibited statistically significant
increases in expression with increasing dose of PCB126.
These genes included Cyp1a1 (cytochrome P450 1A1),
Cyp1b1 (cytochrome P450 1B1), Ugt1a6 (UDP glycosyl-
transferase 1 family, polypeptide A6) and Ugt1a7 (UDP
glycosyltransferase 1 family, polypeptide A7) (Table 3).
The remaining genes in Table 3 represent a novel set of
sensitive genomic biomarkers for chronic exposure to
PCB126.
Identifying Genomic Biomarkers of Subchronic and
Chronic Exposure to TCDD, PCB126 and PCB153
During the 2-year cancer bioassays conducted by the
NTP, it was observed that continuous exposure to DLCs
beyond 30 weeks was necessary to lead to the formation
of hepatic neoplastic lesions (Table 1). Rats treated with
TCDD or PCB126 for 30 weeks, and then with vehicle
control for the remainder of the two-year cancer bioassay
showed no difference in the incidence of hepatocellular
adenoma or cholangiocarcinoma when compared to con-
trol animals [4,5]. This suggests that persistent AhR acti-
vation with long-term alterations in gene expression are
necessary for the development of hepatic neoplasia.
To identify genomic responses which are sustained
throughout chronic exposure, comparative analysis of
time-course microarray data was conducted. Subchronic
(13 weeks) and chronic (52 weeks) exposure to TCDD
(100 ng/kg/day), led to the differential expression of 103
and 299 genes, respectively (Table 2 and additional files
5 and 6). Through comparative analysis of subchronic
and chronic exposure, 75 genes were identified that
exhibited the same differential expression pattern at
both time points (Figures 1 and 2). Following a similar
paradigm for exposure to PCB126 (1000 ng/kg/day),
70 genes were identified that sustained the same differ-
ential expression pattern at both time points (Figures 1
and 2 and additional files 4 and 7). The non-hepatotoxic
PCB153 (Table 1) caused the sustained differential
expression of only 9 genes following subchronic and
chronic exposure (Figures 1 and 2 and additional files 8
and 9). The sustained genomic responses to TCDD,
PCB126 and PCB153 serve as genomic biomarkers of
subchronic and chronic exposure to these compounds.
Identification of Genomic Biomarkers of Exposure to
AhR Ligands
The hepatic gene expression signatures of TCDD and
PCB126, while not identical, did exhibit a great deal of
overlap. Genes that are shared by both expression signa-
tures represent genomic biomarkers of subchronic and
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doses. Forty-one genomic biomarkers were identified
that were shared by the expression signatures of TCDD
and PCB126, but not PCB153 (Table 4 and Figure 3).
These 41 genes are genomic biomarkers of exposure to
two different AhR ligands and may be applicable to
other AhR ligands as biomarkers of exposure (Table 4).
Only one gene, Psat1 (phosphoserine aminotransferase
1), was found to be shared by the expression signatures
of all three compounds (Figures 2 and 3), where its
expression was up-regulated 3- to 8-fold following expo-
sure to TCDD, PCB126, and PCB153.
The sustained differential expression of these 41 AhR
genomic biomarkers at both subchronic and chronic
time-points suggests that these genomic responses are
time-independent. To validate these biomarkers and
determine if the differential expression of these genomic
biomarkers are time-independent, real-time qPCR was
utilized to evaluate hepatic gene expression in female
SD rats at 24 h post-exposure to an acute dose of
TCDD (5 μg/kg, po.) (Table 4). Thirty of these 41 genes
exhibited a 2-fold or greater change in expression 24 h
post-exposure to TCDD (5 μg/kg). While acute expo-
sure to TCDD resulted in less than a 2-fold change in
Table 2 Summary of differentially expressed genes in the livers of female Sprague-Dawley rats following p.o.
exposure to TCDD, PCB126 and PCB153 for 13 and 52 weeks
13 Week Subchronic Exposure Experiment
Exposure Group Number of Differentially Expressed Genes
100 ng/kg/day TCDD 103 (18)
1000 ng/kg/day PCB126 371 (164)
1000 μg/kg/day PCB153 39 (0)
52 Week Chronic Exposure Experiment
Exposure Group Number of Differentially Expressed Genes
100 ng/kg/day TCDD 299 (22)
30 ng/kg/day PCB126 52 (1)
300 ng/kg/day PCB126 128 (15)
1000 ng/kg/day PCB126 216 (171)
1000 μg/kg/day PCB153 47 (1)
Shown are the total number of probe sets exhibiting a ≥ 2-fold change in expression and a p-value < 0.05 following the specified treatments. In parenthesis are
probe sets that are still significant following Benjamini-Hochberg false discovery rate correction.
Table 3 Relative fold change in 16 genes differentially expressed in livers of female Sprague-Dawley rats following
52 weeks of chronic p.o. exposure to 30 ng, 300 ng and 1000 ng/kg/day PCB126
PCB126 dose (ng/kg/d)
Transcript ID Gene Symbol Gene Name 30 300 1000
NM_012540 Cyp1a1
a Cytochrome P450, family 1, subfamily a, polypeptide 1 499* 1263* 1551*
NM_012940 Cyp1b1
a Cytochrome P450, family 1, subfamily b, polypeptide 1 18 866* 2091*
NM_173339 Ceacam10
b CEA-related cell adhesion molecule 10 17 660* 976*
NM_031530 Ccl2 Chemokine (C-C motif) ligand 2 5 11 31*
NM_001039691///NM_057105 Ugt1a6
a UDP glycosyltransferase 1 family, polypeptide A6 3 11* 16*
NM_130407 Ugt1a7
a UDP glycosyltransferase 1 family, polypeptide A7 3 23* 40*
NM_017127 Chka Choline kinase alpha 2 7* 6*
NM_012656 Sparc Secreted acidic cysteine rich glycoprotein 2 2 4*
NM_031569///NM_057098///
XM_001055907///XM_345486
Oprl1///Tcea2 Opioid receptor-like 1///Transcription elongation factor A (SII), 2 2 4 4*
NM_024127 Gadd45a Growth arrest and DNA-damage-inducible 45 alpha 2 4 4*
NM_012600 Me1 Malic enzyme 1 2 2* 4*
NM_001037979 Adipor2
b Adiponectin receptor 2 -3 -2 -6*
NM_012672 Thrb Thyroid hormone receptor beta -3 -3 -3*
NM_032071 Synj2 Synaptojanin 2 -3 -3 -4*
XM_001071608///XM_213849 Nfix Nuclear factor I/X -3 -3 -5*
NM_012988 Nfia Nuclear factor I/A -4 -4 -3*
a Statistically different (p-value = 0.05) between doses using ANOVA with Tukey post-hoc test;
b Statistically different between 300 ng and 1000 ng doses only;
* Genes with p-value < 0.05 following Benjamini-Hochberg FDR correction.
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of the 10 genes exhibited a similar trend in the up or
down regulation observed following subchronic and
chronic exposure to TCDD and PCB126 (Table 4). The
30 genes confirmed through real-time qPCR to be up-
or down-regulated (≥ 2-fold change in expression)
represent time-independent genomic biomarkers of AhR
ligands that are responsive at acute, subchronic and
chronic time-points and may be applied as a diagnostic
and mechanistic tool for the evaluation of AhR-ligand
like activity in the female SD rat model.
T h e4 1A h Rg e n o m i cb i o m a r k e r sw e r ea n a l y z e df o r
the presence of putative DRE sites (5’-GCGTG-3’)
within 5000 bp above and 1000 bp below the tran-
scriptional start site. The gene regulatory sequences
were obtained for 39 of the 41 genes. Sequences for
Alas1 (aminolevulinate, delta-, synthase 1) and Mtmr7
(myotubularin related protein 7) were not available
through the UCSC genome bioinformatic database and
thus prevented analysis for DRE sites. Of the 39 genes
assessed, 25 of the genes contained one or more puta-
t i v eD R Es i t e( T a b l e4 ) .T h i si n c l u d e dg e n e sw h i c h
have been previously shown to be regulated by AhR
ligands including the cytochrome P450 genes Cyp1a1
and Cyp1b1 [10] the UDP glycotransferase genes
Ugt1a6 and Ugt1a7 [27], Hal (histidine ammonia
lyase) [28], Nqo1 (NAD(P)H dehydrogenase, quinone
1) [14], Srd5a1 (steroid-5-alpha-reductase, alpha poly-
peptide) [29] and Tsc22d1 (TSC22 domain family,
member 1; also known as Tgfb1i4) [30].
Phenotypic Anchoring of 52-week Hepatic Gene
Expression to Hepatocellular Adenoma and
Cholangiocarcinoma
Following chronic exposure to TCDD and PCB126 a
significant increase in the incidence of HCA and cholan-
giocarcinoma (CC) is observed in the livers of female SD
rats (Table 1). The appearance of HCA and CC was
observed with 104 weeks of exposure to TCDD and
PCB126, but not at earlier time points or with PCB153.
To relate genomic responses to the observed liver
pathology, comparative analysis was conducted between
the 52 week hepatic gene expression profiles of TCDD,
PCB126 and PCB153, and gene array data from pub-
lished studies on human ICC [24], human HCA [23]
and rat HCA [22].
Human ICC gene expression profiles were obtained
from microarray studies conducted on 13 [25] and 25 [24]
microdissected cholangiocarcinomas. Between the two
studies, 24 genes were identified as exhibiting the same
differential expression pattern in human ICC and in rat
liver following 52 weeks of chronic exposure to TCDD
and/or PCB126, but not PCB153 (Table 5). Among these
g e n e s ,4w e r eu n i q u et ot h eO b a m aet al. (2005) ICC
expression profile, 18 were unique to the Miller et al.
(2009) ICC expression profile and 2 genes were shared
between the two ICC expression profiles. The two genes
that were present in both ICC expression profiles were
Gata6 (GATA binding protein 6) and Timp3 (tissue inhi-
bitor of metalloproteinase 3).
Human and Sprague-Dawley rat HCA gene expression
profiles obtained from microdissected HCA tissues [22]
were used for comparative analysis. Additional rat HCA
gene expression profiles were kindly provided by Dr.
Sun Hee Yim (National Cancer Institute, Bethesda,
MD). Seventeen genes were identified which exhibited
the same differential expression pattern in human HCA
as that seen in the livers of rats exposed for 52 weeks to
TCDD and/or PCB126 (Table 6). Additionally, seven
genes were identified which exhibited the same differen-
tial expression pattern in both rat HCA gene expression
studies and in livers from rats exposed for 52 weeks to
TCDD and/or PCB126, but not PCB153 (Table 6). Inter-
estingly, the genes Gata6, Agt (angiotensinogen (serpin
peptidase inhibitor, clade A, member 8)) and Bhlhb2
(basic helix-loop-helix domain containing, class B2)
Figure 1 Comparison of gene expression profiles following 13
and 52 week exposure to TCDD, PCB126 or PCB153. Venn
diagram depicting the number of genes shared by the hepatic
gene expression profiles in female Sprague-Dawley rats following 13
weeks and 52 weeks of exposure to 100 ng/kg/day TCDD, 1000 ng/
kg/day PCB126 or 1000 μg/kg/day PCB153. In parenthesis is the
total number of significantly different genes differentially expressed
for each exposure group. Genes were deemed significantly different
if they expressed a ≥2-fold change in expression and a p-value ≤
0.05 as determined by student t-test analysis.
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Page 6 of 15Figure 2 Heat map of hepatic gene expression signature for TCDD, PCB126 and PCB153. Heat map depicting hepatic gene expression
signatures in female Sprague-Dawley rats exposed to TCDD, PCB126 and PCB153. The expression signature for each compound represents
genes differentially expressed (≥2-fold change) following both 13 and 52 weeks of exposure.
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Page 7 of 15Table 4 Relative fold change in genes differentially expressed in livers of female Sprague-Dawley rats following 13
weeks and 52 weeks of p.o. exposure to 1000 ng/kg/day PCB126 and 100 ng/kg/day TCDD, and 24 h post-exposure to
5 μg/kg TCDD, p.o
Gene
Symbol
Gene Name 13 wk
PCB126
a
13 wk
TCDD
a
52 wk
PCB126
a
52 wk
TCDD
a
24 h
TCDD
b
DRE site
in Rat
c
DRE site in
Human
c
Cyp1a1 Cytochrome P450, family 1, subfamily a, polypeptide 1 1140* 1026* 1551* 1277* 127881** YES (8) YES (11)
Cyp1b1 Cytochrome P450, family 1, subfamily b, polypeptide 1 519* 743* 2091* 1288* 121
d** YES (9) YES (7)
Ceacam10 CEA-related cell adhesion molecule 10 369* 620* 976* 973* 8.5** NO N/P
Cox8h Cytochrome c oxidase subunit VIII-H (heart/muscle) 66* 312* 24* 27* N/D NO N/A
Nqo1 NAD(P)H dehydrogenase, quinone 1 21* 20 9* 8* 37.0** YES (7) YES (2)
Ugt1a7 UDP glycosyltransferase 1 family, polypeptide A7 14* 85* 40* 33* 24.5** YES (4) YES (2)
Ugt1a6 UDP glycosyltransferase 1 family, polypeptide A6 11* 56* 16* 12* 383.6** YES (6) YES (2)
Cyp1a2 Cytochrome P450, family 1, subfamily a, polypeptide 2 7* 3* 2* 2 38.5** NO YES (3)
Enpp2 Ectonucleotide pyrophosphatase/phosphodiesterase 2 6* 6* 5* 4 2.6** YES (1) NO
Exoc3 Exocyst complex component 3 6* 32* 21* 23* 8.1** NO YES (7)
Aldh3a1 Aldehyde dehydrogenase family 3, member A1 5* 57* 1493* 1156* 10.2** YES (2) YES (5)
Me1 Malic enzyme 1 4* 3 4* 3 2.4** YES (2) YES (2)
Trib3 Tribbles homolog 3 (Drosophila) 2* 8* 13* 16 2.2** YES (1) YES (3)
Tsc22d1 TSC22 domain family, member 1 -2 -2 -6* -4 1.5 YES (4) YES (2)
Gls2 Glutaminase 2 (liver, mitochondrial) -2* -3 -6* -4 -2.5** YES (2) YES (3)
Zfp354a Zinc finger protein 354A -2 -2 -8* -5 -5.3 YES (1) YES (1)
Alas1 Aminolevulinic acid synthase 1 -2* -2 -3 -3 -1.6 N/A YES (2)
Phyh2 Phytanoyl-CoA 2-hydroxylase 2 -2 -4 -3* -3 -1.6 YES (1) YES (1)
Ca2 Carbonic anhydrase 2 -3 -8* -6* -3 -1.9
d NO YES (4)
Sfxn1 Sideroflexin 1 -3* -3* -3* -2 -2.9 NO YES (2)
Mtmr7 Myotubularin related protein 7 -3* -3 -5* -5 -3.0** N/A YES (2)
Pik3c2g Phosphatidylinositol 3-kinase, C2 domain containing,
gamma polypeptide
-3 -2 -3* -3 -1.5 NO NO
Acsm2 Acyl-CoA synthetase medium-chain family member 2 -3 -26 -12* -14 -3.9 YES (2) N/P
Slc29a1 Solute carrier family 29 (nucleoside transporters),
member 1
-3* -3 -3* -2* -2.1 YES (2) YES (1)
Cadps Ca2+-dependent secretion activator -3 -3 -3 -3 -2.6** YES (1) YES (5)
Hal Histidine ammonia lyase -3 -2 -17* -10 -1.3 YES (2) NO
Cyp3a13 Cytochrome P450, family 3, subfamily a, polypeptide 13 -3 -139* -610* -606* -5.6
d** NO N/P
Ptprd Protein tyrosine phosphatase, receptor type, D -3* -2 -3 -2 -1.9 YES (4) YES (2)
Ces3 Carboxylesterase 3 -3* -9 -9* -6 -2.8
d NO YES (2)
Mgst3 Microsomal glutathione S-transferase 3 -3 -3 -4* -4 -3.4** YES (7) YES (4)
Serpina7 Serine (or cysteine) peptidase inhibitor, clade A (alpha-1
antipeptidase, antitrypsin), member 7
-3 -15 -21* -16 -3.3
d NO NO
Nr0b2 Nuclear receptor subfamily 0, group B, member 2 -3* -2 -3* -2 -6.4** NO YES (2)
Aspg Asparaginase homolog (S. cerevisiae) -4* -10 -41* -28 -4.1** YES (8) N/P
Il33 Il33 interleukin 33 -4* -3 -3* -3 -2.1** NO N/P
Ptprn Protein tyrosine phosphatase, receptor type, N -4 -3 -4* -3 -1 YES (2) YES (1)
Srd5a1 Steroid 5 alpha-reductase 1 -4 -6 -14* -11 -2.0
d** YES (1) YES (8)
Enpp3 Ectonucleotide pyrophosphatase/phosphodiesterase 3 -4* -4* -5* -4 -2.3** NO NO
Pdp2 Pyruvate dehydrogenase phosphatase isoenzyme 2 -4 -3 -9* -3 -1.8 YES (1) YES (3)
Ugt1a1 UDP glycosyltransferase 1 family, polypeptide A1 -5* -3 -3* -3 -1.3 YES (4) YES (4)
Slc13a3 Solute carrier family 13 (sodium-dependent
dicarboxylate transporter), member 3
-5 -7 -4* -5 -3.3
d** YES (3) YES (1)
Resp18 Regulated endocrine-specific protein 18 -7 -6 -15* -34 -5.7** NO N/A
Shown are genes for which expression from microarray analysis significantly differed (p < 0.05 as determined by the student t-test), by at least 2-fold, compared
to the control group.
a Fold changes in hepatic gene expression from microarray analysis;
b Fold changes in hepatic gene expression from qPCR at 24 h post-
exposure to TCDD;
c DREs identified in genomic DNA sequences spanning 5000 bp above and 1000 bp below the transcriptional start site. The number in
parenthesis indicates the number of DREs present;
d Values from Ovando et al. 2006; *Genes with p-value < 0.05 following Benjamini-Hochberg FDR correction;
**Statistically different (P ≤ 0.05) between control and treated animals (n = 3) for qPCR; N/P - Gene not present in human genome; N/D - Gene expression could
not be evaluated for that treatment; N/A - Not available in the UCSC genome bioinformatics database.
Ovando et al. BMC Genomics 2010, 11:583
http://www.biomedcentral.com/1471-2164/11/583
Page 8 of 15were down-regulated in ICC and HCA as well as the 52
week expression profiles of TCDD and/or PCB126, but
not PCB153.
Discussion
Toxicological studies conducted by the National Toxi-
cology Program have shown a significant increase in
the incidence of hepatic neoplastic and non-neoplastic
lesions in female SD rats following chronic exposure
to TCDD and PCB126 [4,5,7]. Studies with AhR
knockout mice have shown that the acute toxicity of
TCDD is dependent on the functionality of the AhR
[11,12]. This suggests that the hepatotoxic effects of
TCDD and related dioxin-like compounds (DLCs) are
mediated through the AhR, and changes in gene
expression resulting from activation of this transcrip-
tion factor are likely the principle mode of toxicity of
these compounds. In an effort to identify the genomic
responses that may be contributing to the observed
liver toxicity, toxicogenomics was conducted to pro-
vide a comprehensive description of hepatic gene
expression with acute exposure to TCDD and subchro-
n i ca n dc h r o n i ce x p o s u r et oT C D Da n dP C B 1 2 6 ,t h e
most potent dioxin-like PCB.
Through the comparative analysis of time-course
microarray data, hepatic gene expression signatures of
subchronic and chronic exposure to TCDD, PCB126
and PCB153 were identified (Figures 1 &2). The hepatic
gene expression signature of PCB126 (1000 ng/kg/day)
consists of 70 genes which show sustained differential
expression at both subchronic (13 weeks) and chronic
(52 weeks) time points (Figure 1). In addition, a dose
response analysis of hepatic gene expression was con-
ducted following 52 weeks of chronic exposure to 30 ng,
300 ng and 1000 ng/kg/day PCB126. Gene array analysis
showed a positive correlation between PCB126 dose and
the number of genes differentially expressed (Table 2).
A similar dose response relationship has been reported
for female mice subjected to an acute exposure to
PCB126 [31]. Comparative analysis of the hepatic
expression profiles of chronic (52 weeks) exposure to 30
ng, 300 ng and 1000 ng/kg/day PCB126 identified 16
genes which were differentially expressed at all three
concentrations (Table 3). Interestingly, of those 16
genes, Ccl2 (chemokine (C-C motif) ligand 2), Chka
(choline kinase alpha), Thrb (thyroid hormone receptor
beta) and Synj2 (synaptojanin 2) are not present in the
13- and 52 week hepatic gene expression signature of
PCB126 (Figure 2). This indicates that even though dif-
ferential expression of Ccl2, Chka, Thrb and Synj2 are
sensitive endpoints of chronic PCB126 exposure, as evi-
dent in their responsiveness at 30 ng/kg/day PCB126,
these changes do not manifest themselves following 13
weeks of subchronic exposure to 1000 ng/kg/day
PCB126. These four genes help illustrate the caution
that one must use in categorizing a gene as a biomarker
of exposure. As seen in these results, Ccl2, Chka, Thrb
and Synj2 are examples of sensitive genomic responses
to chronic PCB126 exposure, however, they do not exhi-
bit the early subchronic responsiveness that would make
them beneficial as biomarkers in early stage identifica-
tion of PCB126 exposure.
Pathological data shows that continuous exposure to
TCDD and PCB126 beyond a period of 13 weeks is
necessary to cause the formation of hepatic neoplastic
and non-neoplastic lesions [4,5]. Considering the rele-
vance of genomic responses to the toxicity of DLCs,
these data suggest that changes in gene expression that
are sustained throughout chronic treatment are playing
a pivotal role in the development of hepatic lesions.
Seventy-five and 70 genes were identified which showed
sustained differential expression following subchronic
(13 weeks) and chronic (52 weeks) exposure to TCDD
and PCB126, respectively (Figures 1 and 2). The sus-
tained differential expression of these genes over a 52
week span suggests that these genes are likely playing
an important role in the hepatotoxic effects of TCDD
and PCB126. Nine genes showed sustained differential
expression following subchronic and chronic exposure
to PCB153 (Figures 1 and 2). Only one gene, Psat1,w a s
differentially expressed (up-regulated 3- to 8-fold) in the
expression signatures of PCB153, TCDD and PCB126
(Figure 3). Psat1 is a phosphoserine aminotransferase
involved in serine biosynthesis whose expression has
Figure 3 Comparison of hepatic gene expression signatures for
TCDD, PCB126 and PCB153. Venn diagram depicting the number
of genes shared by the hepatic gene expressions signatures in
female Sprague-Dawley rats following subchronic and chronic
exposure to TCDD (100 ng/kg/day), PCB126 (1000 ng/kg/day) or
PCB153 (1000 μg/kg/day). In parenthesis is the total number of
genes differentially expressed for each compound following both 13
and 52 weeks of exposure. The 41 genes shared in common by
exposures to TCDD and PCB126 represent genomic biomarkers of
subchronic and chronic exposure to AhR ligands or the time
independent gene expression signature of the AhR ligands.
Ovando et al. BMC Genomics 2010, 11:583
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Page 9 of 15Table 5 Relative fold change in genes differentially expressed in human intrahepatic cholangiocarcinoma (ICC) and
the hepatic gene expression profiles of rats exposed to TCDD, PCB126, and PCB153 p.o. for 52 weeks
Transcript ID Rat
Ortholog
Rat Gene Name Human
Ortholog
ICC
[25]
ICC
[24]
TCDD
100 ng/kg/day
PCB126
1000 ng/kg/day
PCB153
1000 μg/kg/day
NM_144755 Trib3 Tribbles homolog 3
(Drosophila)
TRIB3 18 N/C 16 13 N/C
NM_016988 Acp2 Acid phosphatase 2,
lysosomal
ACP2 2 N/C 3 2 N/C
NM_021261 Tmsb10 Thymosin, beta 10 TMSB10 2 N/C 2 N/C N/C
NM_017059 Bax Bcl2-associated X
protein
BAX 4 N/C 2 N/C N/C
NM_019287 Apob Apolipoprotein B APOB N/C -3 -9 N/C N/C
NM_019185 Gata6 GATA binding protein 6 GATA6 -4 -5 -3 -4 N/C
NM_013219 Cadps Ca2+-dependent
secretion activator
CADPS N/C -16 -3 -3 N/C
NM_012886 Timp3 Tissue inhibitor of
metalloproteinase 3
(Sorsby fundus
dystrophy,
pseudoinflammatory)
TIMP3 -11 -3 -2 N/C N/C
NM_017158 Cyp2c7 Cytochrome P450,
family 2, subfamily c,
polypeptide 7
CYP2C9 N/C -3 -2 -2 N/C
NM_134432 Agt Angiotensinogen
(serpin peptidase
inhibitor, clade A,
member 8)
AGT N/C -6 -2 N/C N/C
NM_053598 Nudt4 Nudix (nucleoside
diphosphate linked
moiety X)-type motif 4
NUDT4 -3 N/C -2 N/C N/C
NM_013029 St8sia3 ST8 alpha-N-acetyl-
neuraminide alpha-2,8-
sialyltransferase 3
ST8SIA3 -2 N/C -2 N/C N/C
NM_012596 Lepr Leptin receptor LEPR -8 N/C -2 N/C N/C
NM_022501 Crip2 Cysteine-rich protein 2 CRIP -9 N/C -3 -3 N/C
NM_031132 Tgfbr2 Transforming growth
factor, beta receptor II
TGFBR2 -4 N/C -3 N/C N/C
NM_001025271 Sfpq Splicing factor proline/
glutamine rich
(polypyrimidine tract
binding protein
associated)
SFPQ -5 N/C -3 N/C N/C
NM_001007235 Itpr1 Inositol 1,4,5-
triphosphate receptor 1
ITPR1 -3 N/C -3 -3 N/C
NM_053328 Bhlhb2 Basic helix-loop-helix
domain containing,
class B2
BHLHB2 -4 N/C -4 N/C N/C
NM_001013137 Cxcl14 Chemokine (C-X-C
motif) ligand 14
CXCL14 -11 N/C -4 -10 N/C
NM_031561 Cd36 Cd36 antigen CD36 -5 N/C -6 -4 N/C
NM_031135 Klf10 Kruppel-like factor 10 KLF10 -4 N/C -10 N/C N/C
NM_022251 Enpep Glutamyl
aminopeptidase
ENPEP -2 N/C -12 -5 N/C
NM_031648 Fxyd1 FXYD domain-
containing ion
transport regulator 1
FXYD1 -14 N/C N/C -2 N/C
NM_053698 Cited2 Cbp/p300-interacting
transactivator, with Glu/
Asp-rich carboxy-
terminal domain, 2
CITED2 -4 N/C N/C -4 N/C
N/C indicates no change in gene expression for that treatment.
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Page 10 of 15been shown to be up-regulated in colon adenocarci-
noma [32], colorectal cancer [33] and breast cancer [34].
Additionally, increased expression of Psat1 in colorectal
cancer and breast cancer is associated with a poor
regression of tumor metastases following therapy
[33,34]. The increase expression of Psat1 following
TCDD, PCB126 and PCB153 treatments suggests that
its response is not specific to DLCs. The identification
of unique gene expression profiles in Sprague-Dawley
rats exposed to DLCs (TCDD or PCB126) versus non-
DLCs (PCB153) corroborates similar observations pre-
viously reported in ovariectomized C57BL/6 mice [35].
From the hepatic gene expression signatures of PCB126
and TCDD, 41 genomic biomarkers were identified that
are shared by both compounds, following 13 and 52
weeks of exposure (Table 4). The observation that these
41 genomic biomarkers are shared by two AhR ligands
suggests that differential expression of these genes
requires AhR activation. Of the 41 AhR-ligand genomic
biomarkers, 30 exhibited a 2-fold or greater change in
Table 6 Relative fold change in genes differentially expressed in human hepatocellular adenoma (HCA), rat HCA and
the hepatic gene expression profiles of rats exposed to TCDD, PCB126, and PCB153 p.o. for 52 weeks
Transcript ID Gene
Symbol
Rat Gene Name Human
Ortholog
HCA
[23]
HCA
[22]
TCDD
100 ng/
kg/day
PCB126
1000 ng/
kg/day
PCB153
1000 μg/
kg/day
NM_053401 Ngfrap1 Nerve growth factor receptor (TNFRSF16) associated
protein 1
NGFRAP1 N/C 13 8 6 N/C
NM_012752 Cd24 CD24 antigen CD24 10 N/C 7 4 N/C
NM_017127 Chka Choline kinase alpha CHKA 2 N/C 5 6 N/C
NM_057104 Enpp2 Ectonucleotide pyrophosphatase/phosphodiesterase
2
ENPP2 4 N/C 4 5 N/C
NM_017166 Stmn1 Stathmin 1 STMN1 2 N/C 4 N/C 2
NM_145878 Fabp5 Fatty acid binding protein 5, epidermal FABP5 2 N/C 4 3 N/C
NM_022298 Tuba1 Tubulin, alpha 1 TUBA4A N/C 11 3 N/C N/C
NM_053515 Slc25a4 Solute carrier family 25 (mitochondrial carrier;
adenine nucleotide translocator), member 4
SLC25A4 N/C 8 3 N/C N/C
NM_012862 Mgp Matrix Gla protein MGP 4 N/C 3 3 N/C
NM_012946 Sparcl1 SPARC-like 1 (mast9, hevin) SPARCL1 3 N/C 2 2 N/C
NM_030987 Gnb1 Guanine nucleotide binding protein, beta 1 GNB1 2 N/C N/C 3 N/C
NM_031795 Ugcg UDP-glucose ceramide glucosyltransferase UGCG 2 N/C N/C N/C 2
NM_023103 Mug1 Murinoglobulin 1 homolog (mouse) none N/C -5 -2 N/C N/C
NM_134432 Agt Angiotensinogen (serpin peptidase inhibitor, clade
A, member 8)
AGT N/C -5 -2 N/C N/C
NM_012899 Alad Aminolevulinate, delta-, dehydratase ALAD -2 N/C -2 -3 N/C
NM_053770 Argbp2 Arg/Abl-interacting protein ArgBP2 ARGBP2 -3 N/C -2 N/C N/C
NM_022508 Mthfd1 Methylenetetrahydrofolate dehydrogenase (NADP+
dependent), methenyltetrahydrofolate
cyclohydrolase, formyltetrahydrofolate synthase
MTHFD1 -5 N/C -2 N/C N/C
NM_012716 Slc16a1 Solute carrier family 16 (monocarboxylic acid
transporters), member 1
SLC16A1 -3 N/C -2 N/C N/C
NM_013177 Got2 Glutamate oxaloacetate transaminase 2,
mitochondrial
GOT2 -2 N/C N/C N/C -2
NM_012737 Apoa4 Apolipoprotein A-IV APOA4 N/C -9 -3 -4 N/C
NM_053923 Pik3c2g Phosphatidylinositol 3-kinase, C2 domain containing,
gamma polypeptide
PIK3C2G -3 N/C -3 -3 N/C
NM_024484 Alas1 Aminolevulinic acid synthase 1 ALAS1 -3 N/C -3 -3 2
NM_019185 Gata6 GATA binding protein 6 GATA6 -3 N/C -3 -4 N/C
NM_053328 Bhlhb2 Basic helix-loop-helix domain containing, class B2 BHLHB2 -2 N/C -4 N/C N/C
XM_001076124///
XM_001076147///
XM_001076171///
XM_341825
Prodh2 Proline dehydrogenase (oxidase) 2 PRODH2 -3 N/C N/C -3 N/C
NM_147206 Cyp3a13 Cytochrome P450, family 3, subfamily a, polypeptide
13
CYP3A4 N/C -9 -606 -610 N/C
N/C indicates no change in gene expression for that treatment.
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TCDD, as determined by real-time qPCR. In addition,
approximately 40%of these genes have shown a 2-fold
change in expression following acute exposure to TCDD
in other studies conducted on female and/or male Spra-
gue-Dawley rats [14,27], adding further support that
these genomic biomarkers represent time-independent
primary responses in gene expression to AhR ligands.
Ten of the AhR genomic biomarkers resulted in a less
than 2-fold change following acute exposure to TCDD,
however, 9 of these biomarkers exhibited a similar trend
in the up or down regulation observed following sub-
c h r o n i ca n dc h r o n i ce x p o s u r et oT C D Da n dP C B 1 2 6
(Table 4). Furthermore, other microarray studies have
shown that following an acute exposure to TCDD, the
majority of these genomic biomarkers exhibit a similar
response as that seen in our study [14,29,30], thus pro-
viding further evidence for their roles as biomarkers.
Seven of the 41 genomic biomarkers are members of the
“AhR gene battery” which are a group of genes known to
be regulated by the AhR [36]. Genomic biomarker genes
which fall into this category include CYP1a1, CYP1a2
(cytochrome P450 1A2), CYP1b1, Nqo1, Ugt1a6, Ugt1A7
and Aldh3a1 (aldehyde dehydrogenase 3A1).M o r en o v e l
genes included among the 41 genomic biomarkers include
genes involved in trafficking/transport (Cadps, Exoc3, Ser-
pina7, Slc13a3 and Slc29a1), cell adhesion (Ceacam10 and
Enpp2), cell signaling (Ptprd, Ptprn and Trib3) and devel-
opment/differentiation (Enpp3 and Srd5a1). Enpp2 (Ecto-
nucleotide pyrophosphatase/phosphodiesterase 2; also
known as autotaxin), a tumor cell motility stimulating fac-
tor [37], was up-regulated following TCDD and PCB126
exposure. This agrees with previous observations implicat-
ing Enpp2 as being one of the most commonly up-
regulated genes in cancer cells and being widely involved
in tumor progression, invasion and metastasis [38]. Ptprd
(Receptor-type tyrosine-protein phosphatase delta), a pro-
tein tyrosine phosphatase, has been identified as a tumor
suppressor [39,40] whose expression is down-regulation in
breast, colon and glioblastoma tumors [39,41]. The down-
regulation of Ptprd following TCDD and PCB126 expo-
sure likely contributes to the neoplastic effects of the
compounds. Trib3 (Tribbles homolog 3 (Drosophila)) is
a regulatory protein which has been shown to be
up-regulated following stressful conditions [42,43], consis-
tent with its up-regulation following TCDD and PCB126
exposure.
Twenty-five of the 41 AhR-ligand genomic biomarkers
contained one or more putative DRE within 5000 bp
upstream and 1000 bp downstream from the transcrip-
tional start site (Table 4). However, genes such as
Cyp3a13 (cytochrome P450 3A13), Ces3 (carboxylesterase
3) and Serpina7 (serine (or cysteine) peptidase inhibitor,
clade A (alpha-1 antiproteinase, antitrypsin), member 7)
did not contain a putative DRE in the region examined
(-5000 bp to +1000 bp), suggesting that an activated AhR
may not directly bind to these genes. Interestingly, even
though Cyp3a13, Ces3 and Serpina7 do not contain any
DREs in their promoter region, their acute sensitivity to
TCDD has been previously shown to be dependent on a
functional AhR [13]. This indicates that the presence or
lack of a DRE in the promoter region does not solely
determine the response of a gene following TCDD expo-
sure; it is also possible that a DRE located outside the
region examined here is able to influence gene expression.
In order to relate changes in gene expression to the
observed hepatotoxicity, the 52 week hepatic gene
expression profiles from TCDD and PCB126 treated rats
were compared to the expression profiles from previously
published studies [22,24] that examined hepatic neoplas-
tic lesions similar to those observed in the NTP studies.
Through this approach, an attempt was made to identify
common genes which may play a role in the development
and progression of the neoplastic effects observed with
DLCs. This comparison identified 24, 17 and 7 genes
which were differentially expressed with exposure to
DLCs and human ICC, human HCA and rat HCA,
respectively (Tables 5 and 6). Interestingly, of the genes
common to both DLC exposure and the examined dis-
ease states, Alas1, Cadps (Ca2+-dependent secretion acti-
vator), Cyp3a13, Enpp2, Pik3c2g (phosphatidylinositol 3-
kinase, C2 domain containing, gamma polypeptide) and
Trib3 were also present among the 41 time independent
AhR genomic biomarkers. For both of the HCA and ICC
studies there were genes which did not overlap between
the similar disease states which is likely due to inter-indi-
vidual differences in the tumor micro-environment,
environmental conditions and other genetic components.
The genes Gata6 and Timp3 were down-regulated in
both of the human ICC expression profiles and follow-
ing TCDD exposure. Gata6 was also down-regulated
following PCB126 exposure and in the human HCA
expression profile. Additionally, the genes Bhlhb2, Agt
and Gata6 were down-regulated in the ICC and HCA
disease states and following exposure to DLCs. Gata6 is
a zinc finger transcription factors which can regulate
gene expression and cell cycle progression [44,45].
Expression of Gata6 is significantly depressed in most
human adrenocortical tumors [46,47] and it has been
hypothesized that decreased expression of Gata6 may
be an important event for the escape of tumor cells
from normal control mechanisms [48]. Timp3 is a
matrix metalloproteinase with proapoptotic activity [49]
whose expression is significantly lower in human cho-
langiocarcinomas [50]. It has been suggested that Timp3
may serve as a tumor suppressor gene in cholangiocarci-
noma [50]. Bhlhb2 (also known as Dec1)i sah y p o x i a -
induced gene whose expression is elevated in several
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Bhlhb2 in HCA, ICC and following TCDD exposure
suggest that these tumor micro-environments are not
hypoxic. Agt, is a known precursor of angiotensin I and
has shown antitumor effects in vitro [54]and in vivo
[55] by inducing apoptosis and decreasing endothelial
cell proliferation [56]. The down-regulation of Agt in
HCA, ICC and following TCDD exposure likely contri-
butes to the formation of neoplastic lesions.
It should be noted that of the 50 genes shared by the 52-
week gene expression data (TCDD, PCB126, and PCB153)
and gene expression data from the published reports of
ICC and HCA, only 4 genes (Got2, Ugcg, Stmn1 and
Alas1) were found to be differentially expressed by the
non-DLC PCB153. Gene expression of Got2 (glutamic-
oxaloacetic transaminase 2, mitochondrial (aspartate ami-
notransferase 2), a mitochondrial enzyme involved in
energy transduction [57], was down-regulated in the
PCB153 and human HCA expression profiles while Ugcg
(UDP-glucose ceramide glucosyltransferase), an enzyme
involved in glycosphingolipid biosynthesis [58], gene
expression was up-regulated in these two expression pro-
files. Stmn1 (stathmin 1), a cellular protein involved in
mictotubule destabilization [59], is over expressed in a
wide variety of human cancers including liver, breast, lung
and prostate cancer [60-63]. Stmn1 was up-regulated in
the TCDD, PCB153 and human HCA expression profiles
suggesting that while it is a good marker for different
types of human cancer, it may not be a valid biomarker
for DLC exposure in Sprague Dawley rats. Gene expres-
sion of Alas1,a ne n z y m ei n v o l v e di nh e m eb i o s y n t h e s i s
[64], was down-regulated in the TCDD, PCB126 and
human HCA profiles but up-regulated in the PCB153
expression profile, suggesting that down-regulation of
Alas1 may promote tumor development.
Conclusions
Toxicogenomic analysis has identified hepatic genomic
biomarkers of exposure to the AhR ligands, TCDD and
PCB126; and the non-dioxin-like compound, PCB153.
From these genomic biomarkers, time-independent hepa-
tic gene expression signatures were constructed that are
unique to TCDD, PCB126 and PCB153. In addition to
identifying gene expression signatures for the dioxin-like
compounds TCDD and PCB126, 41 common genomic
biomarkers were identified which are shared by these
AhR ligands. These 41 common genomic biomarkers
may serve as biomarkers of exposure to other AhR
ligands and can be used in the risk assessment of other
environmental toxins believed to exert their effect
through AhR activation. Together, the data collected in
this study can serve to guide future investigations in
assessing risk of dioxin-like compounds and elucidating
the mechanisms of action by which dioxin-like com-
pounds induce their hepatotoxic and carcinogenic effects.
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subchronic p.o. exposure to 1000 ng/kg/day PCB126 A list of the
371 genes differentially expressed genes following 13 weeks of
subchronic exposure to 1000 ng/kg/day PCB126. A gene was considered
to be differentially expressed if it displayed a gene expression fold
change of 2 or greater.
Additional file 8: Microarray gene expression following 13 weeks of
subchronic p.o. exposure to 1000 μg/kg/day PCB153 A list of the 39
genes differentially expressed following 13 weeks of subchronic exposure
to 1000 μg/kg/day PCB153. A gene was considered to be differentially
expressed if it displayed a gene expression fold change of 2 or greater.
Additional file 9: Microarray gene expression following 52 weeks of
chronic p.o. exposure to 1000 μg/kg/day PCB153 A list of the 47
genes differentially expressed following 52 weeks of chronic exposure to
1000 μg/kg/day PCB153. A gene was considered to be differentially
expressed if it displayed a gene expression fold change of 2 or greater.
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